How CBX proteins regulate normal and leukemic blood cells

Anne P. de Groot, Gerald de Haan*

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    12 Downloads (Pure)

    Abstract

    Hematopoietic stem cell (HSC) fate decisions are dictated by epigenetic landscapes. The Polycomb Repressive Complex 1 (PRC1) represses genes that induce differentiation, thereby maintaining HSC self-renewal. Depending on which chromobox (CBX) protein (CBX2, CBX4, CBX6, CBX7, or CBX8) is part of the PRC1 complex, HSC fate decisions differ. Here, we review how this occurs. We describe how CBX proteins dictate age-related changes in HSCs and stimulate oncogenic HSC fate decisions, either as canonical PRC1 members or by alternative interactions, including non-epigenetic regulation. CBX2, CBX7, and CBX8 enhance leukemia progression. To target, reprogram, and kill leukemic cells, we suggest and describe multiple therapeutic strategies to interfere with the epigenetic functions of oncogenic CBX proteins. Future studies should clarify to what extent the non-epigenetic function of cytoplasmic CBX proteins is important for normal, aged, and leukemic blood cells.

    Original languageEnglish
    Number of pages19
    JournalFEBS Letters
    DOIs
    Publication statusPublished - 2024

    Keywords

    • aging
    • CBX
    • epigenetics
    • hematopoiesis
    • HSC
    • leukemia
    • Polycomb
    • PRC1
    • subcellular CBX localization

    Fingerprint

    Dive into the research topics of 'How CBX proteins regulate normal and leukemic blood cells'. Together they form a unique fingerprint.

    Cite this